Vericel Earnings Call Highlights MACI-Fueled Growth

Vericel Corporation ((VCEL)) has held its Q4 earnings call. Read on for the main highlights of the call.

Vericel Corporation’s latest earnings call struck a broadly upbeat tone, underscoring record revenue, expanding margins and a fortified balance sheet, even as management flagged near‑term margin pressure and execution risks. Leaders emphasized that conservative 2026 guidance intentionally leaves room for upside, suggesting confidence in MACI’s momentum, the enlarged sales force and pipeline catalysts.

Record Revenue Underscore Growth Trajectory

Vericel reported Q4 2025 revenue of $92.9 million, up 23% year over year, capping a record full‑year revenue haul of $276.3 million that topped the high end of guidance. The performance highlights continued demand strength across the portfolio and shows the company is sustaining double‑digit growth at increasing scale.

MACI Franchise Drives the Business

MACI remained the growth engine with Q4 revenue of $84.1 million, rising 23% year over year and 51% sequentially from Q3. For 2025, MACI generated $239.5 million in revenue, up 21% and extending a roughly 24% compound annual growth rate over nine years with more than 20,000 patients treated.

Margins Reach New Highs

Profitability surged as Q4 gross profit topped $73 million, translating to about 79% gross margin, while adjusted EBITDA exceeded $37 million for a 40% margin, both quarterly records. For the full year, gross margin improved to 74% and adjusted EBITDA margin reached 26%, expanding roughly 200 and over 300 basis points, respectively.

Balance Sheet Strength and Cash Generation

The company ended 2025 with roughly $200 million in cash and investments, an increase of $35 million in the second half, and it carries no debt. Operating cash flow of $52 million for the year gives Vericel ample flexibility to fund commercial expansion, clinical programs and manufacturing investments without stressing the balance sheet.

Sales Force Expansion and MACI Arthro Adoption

Vericel completed a roughly 30% expansion of its MACI sales footprint, adding about 30 new representatives and meaningfully increasing territory coverage. Around 1,000 surgeons have now been trained on MACI Arthro, and those trained and implanting are showing higher biopsy and implant growth along with stronger conversion rates.

Clinical and Manufacturing Milestones

On the development front, the company initiated the Phase III MACI Ankle MASCOT trial in the fourth quarter, signaling a push to broaden MACI’s label into ankle indications. Vericel also remains on track to start commercial manufacturing at its new Burlington facility in 2026 and is pursuing a staged ex‑U.S. rollout, targeting a U.K. launch around 2027.

Burn Care Growth and Cross‑Selling Synergies

Burn Care delivered Q4 revenue of $8.8 million, beating guidance and contributing to full‑year Burn Care revenue of $36.8 million, including $32.1 million from Epicel and $4.7 million from NexoBrid. The consolidated Burn Care team, now operating across 17 territories and cross‑selling both products, has secured NexoBrid orders from more than 70 of roughly 90 target accounts.

Conservative 2026 Outlook Leaves Room for Upside

Management framed 2026 guidance as intentionally cautious, excluding potential benefits from faster sales rep ramp, accelerated MACI Arthro adoption or any BARDA‑related NexoBrid revenue. This prudence signals discipline around expectations but also sets up the possibility of outperformance if these incremental growth drivers materialize more quickly than modeled.

Early 2026 Margin Dip and Cost Pressure

The outlook calls for margin compression in the first quarter of 2026, with guided gross margin around 70% and adjusted EBITDA margin near 10%, well below the Q4 2025 highs. Higher operating expenses, including about $220 million for 2026 with incremental SG&A from new reps and stepped‑up R&D for the MACI Ankle trial, are expected to weigh on near‑term profitability until revenue scales.

Pricing Dependence and Sales Ramp Risks

Management acknowledged that price increases were a meaningful growth driver in 2025, prompting investor questions about the balance between pricing and volume‑driven expansion. The roughly 30% territory build‑out introduces execution risk and a long sales cycle, and while the company believes rep productivity can rebound to 2025 levels as early as next year, the exact timing remains uncertain.

BARDA and NexoBrid Timing Remains Unclear

A potential BARDA award related to NexoBrid stockpiling could represent a significant upside lever, but it was left out of 2026 guidance due to government funding and timing uncertainty. Management still views the opportunity as likely over time, yet investors will have to wait for clearer visibility on when, and at what scale, such revenue might hit the income statement.

Guidance Points to Strong 2026 with Upside Optionality

For 2026, Vericel guided total revenue to approximately $316 million to $326 million, including MACI at about $280 million to $286 million and Burn Care at roughly $36 million to $40 million, implying a run‑rate near $9 million to $10 million per quarter. The company expects more than 20% Q1 revenue growth, full‑year gross margin around 75% and adjusted EBITDA margin near 27%, supported by its $200 million cash position even as operating expenses reach about $220 million.

Vericel’s call painted the picture of a company in the enviable position of pairing robust growth and premium margins with a clean balance sheet, anchored by MACI’s sustained momentum. While investors must weigh near‑term margin compression, pricing sensitivity and execution around the expanded sales force, the long‑term narrative remains firmly growth‑oriented with multiple levers for upside beyond the conservative 2026 guide.